User login
BEST PRACTICES IN: Incorporating Continuous Glucose Monitoring Into Your Practice
A supplement to Clinical Endocrinology News. This supplement was sponsored by DexCom, Inc.
• Interpreting the Data
• Time Needed to Interpret Data at Follow-Up Visits
• Training Patients to Initiate CGM
• Follow-Up Visits
• Summary
Faculty/Faculty Disclosure
Davida F. Kruger, MSN, APN-BC, BC-ADM
Certified Nurse Practitioner and Diabetes Educator
Henry Ford Health System
Division of Endocrinology
Diabetes, Bone and Mineral Disorders
Detroit, MI
Ms Kruger is a consultant for Abbott Laboratories, Amylin Pharmaceuticals, Inc., Animas Corporation, a Johnson & Johnson Company, Calibra Medical, Inc., Eli Lilly and Company, and Novo Nordisk; serves on the speakers' bureau for Amylin, Lilly, Lilly-Amylin Alliance, and Novo Nordisk; and has received clinical research grant funding from Amylin, Calibra, DexCom, Inc., Eli Lilly and Company, Halozyme Therapeutics, Hoffman-La Roche Ltd, and the National Institutes of Health (NIH). She is also a stock shareholder of Amylin, DexCom, Hygieia Medical, and Patton Medical Devices and serves on the advisory board for Abbott, Animas, CADRE, CLINICAL ENDOCRINOLOGY NEWS, Eli Lilly, GlaxoSmithKline, Merck & Co., Inc., Novo Nordisk, Patton Medical Devices, and Tethys Bioscience, Inc.
Copyright © 2010 Elsevier Inc.
A supplement to Clinical Endocrinology News. This supplement was sponsored by DexCom, Inc.
• Interpreting the Data
• Time Needed to Interpret Data at Follow-Up Visits
• Training Patients to Initiate CGM
• Follow-Up Visits
• Summary
Faculty/Faculty Disclosure
Davida F. Kruger, MSN, APN-BC, BC-ADM
Certified Nurse Practitioner and Diabetes Educator
Henry Ford Health System
Division of Endocrinology
Diabetes, Bone and Mineral Disorders
Detroit, MI
Ms Kruger is a consultant for Abbott Laboratories, Amylin Pharmaceuticals, Inc., Animas Corporation, a Johnson & Johnson Company, Calibra Medical, Inc., Eli Lilly and Company, and Novo Nordisk; serves on the speakers' bureau for Amylin, Lilly, Lilly-Amylin Alliance, and Novo Nordisk; and has received clinical research grant funding from Amylin, Calibra, DexCom, Inc., Eli Lilly and Company, Halozyme Therapeutics, Hoffman-La Roche Ltd, and the National Institutes of Health (NIH). She is also a stock shareholder of Amylin, DexCom, Hygieia Medical, and Patton Medical Devices and serves on the advisory board for Abbott, Animas, CADRE, CLINICAL ENDOCRINOLOGY NEWS, Eli Lilly, GlaxoSmithKline, Merck & Co., Inc., Novo Nordisk, Patton Medical Devices, and Tethys Bioscience, Inc.
Copyright © 2010 Elsevier Inc.
A supplement to Clinical Endocrinology News. This supplement was sponsored by DexCom, Inc.
• Interpreting the Data
• Time Needed to Interpret Data at Follow-Up Visits
• Training Patients to Initiate CGM
• Follow-Up Visits
• Summary
Faculty/Faculty Disclosure
Davida F. Kruger, MSN, APN-BC, BC-ADM
Certified Nurse Practitioner and Diabetes Educator
Henry Ford Health System
Division of Endocrinology
Diabetes, Bone and Mineral Disorders
Detroit, MI
Ms Kruger is a consultant for Abbott Laboratories, Amylin Pharmaceuticals, Inc., Animas Corporation, a Johnson & Johnson Company, Calibra Medical, Inc., Eli Lilly and Company, and Novo Nordisk; serves on the speakers' bureau for Amylin, Lilly, Lilly-Amylin Alliance, and Novo Nordisk; and has received clinical research grant funding from Amylin, Calibra, DexCom, Inc., Eli Lilly and Company, Halozyme Therapeutics, Hoffman-La Roche Ltd, and the National Institutes of Health (NIH). She is also a stock shareholder of Amylin, DexCom, Hygieia Medical, and Patton Medical Devices and serves on the advisory board for Abbott, Animas, CADRE, CLINICAL ENDOCRINOLOGY NEWS, Eli Lilly, GlaxoSmithKline, Merck & Co., Inc., Novo Nordisk, Patton Medical Devices, and Tethys Bioscience, Inc.
Copyright © 2010 Elsevier Inc.
BEST PRACTICES IN: Continuous Glucose Monitoring and Multiple Daily Injections
A supplement to Clinical Endocrinology News. This supplement was sponsored by DexCom, Inc.
• How CGM Works
• Benefits of CGM
• CGM in MDI and CSII
• Education Required Implementing CGM
• Insurance Coverage - Improving
• Anecdotal Experience
• Summary
Faculty/Faculty Disclosure
Satish K. Garg, MD
Professor of Medicine & Pediatrics
Director, Adult Program
University of Colorado, Denver
Denver, Colorado
Editor-in-Chief
Diabetes Technology & Therapeutics
Dr Garg is a consultant for and has received clinical research grant funding from Abbott Laboratories, DexCom, Inc., and Medtronic, Inc.
A supplement to Clinical Endocrinology News. This supplement was sponsored by DexCom, Inc.
• How CGM Works
• Benefits of CGM
• CGM in MDI and CSII
• Education Required Implementing CGM
• Insurance Coverage - Improving
• Anecdotal Experience
• Summary
Faculty/Faculty Disclosure
Satish K. Garg, MD
Professor of Medicine & Pediatrics
Director, Adult Program
University of Colorado, Denver
Denver, Colorado
Editor-in-Chief
Diabetes Technology & Therapeutics
Dr Garg is a consultant for and has received clinical research grant funding from Abbott Laboratories, DexCom, Inc., and Medtronic, Inc.
A supplement to Clinical Endocrinology News. This supplement was sponsored by DexCom, Inc.
• How CGM Works
• Benefits of CGM
• CGM in MDI and CSII
• Education Required Implementing CGM
• Insurance Coverage - Improving
• Anecdotal Experience
• Summary
Faculty/Faculty Disclosure
Satish K. Garg, MD
Professor of Medicine & Pediatrics
Director, Adult Program
University of Colorado, Denver
Denver, Colorado
Editor-in-Chief
Diabetes Technology & Therapeutics
Dr Garg is a consultant for and has received clinical research grant funding from Abbott Laboratories, DexCom, Inc., and Medtronic, Inc.
BEST PRACTICES IN:Preventing Hypoglycemia by Continuous Glucose Monitoring
Preventing Hypoglycemia by Continuous Glucose Monitoring
A supplement to Clinical Endocrinology News. This supplement was sponsored by Dexcom.
• Home Glucose Monitoring
• Continuous Glucose Monitoring
• Summary
Faculty
Steven V. Edelman, MD
Professor of Medicine
University of California, San Diego
La Jolla, California
Dr. Edelman is a consultant to and speaker for Amylin Pharmaceuticals, Inc., Eli Lilly and Company, Novo Nordisk A/S and sanofi-aventis U.S., LLC.
Jacqueline Kung, MD
Endocrinology Fellow
University of California, San Diego Medical Center
VA Medical Center of San Diego
San Diego, California
Dr. Kung has nothing to disclose.
Copyright © 2009 Elsevier Inc.
A supplement to Clinical Endocrinology News. This supplement was sponsored by Dexcom.
• Home Glucose Monitoring
• Continuous Glucose Monitoring
• Summary
Faculty
Steven V. Edelman, MD
Professor of Medicine
University of California, San Diego
La Jolla, California
Dr. Edelman is a consultant to and speaker for Amylin Pharmaceuticals, Inc., Eli Lilly and Company, Novo Nordisk A/S and sanofi-aventis U.S., LLC.
Jacqueline Kung, MD
Endocrinology Fellow
University of California, San Diego Medical Center
VA Medical Center of San Diego
San Diego, California
Dr. Kung has nothing to disclose.
Copyright © 2009 Elsevier Inc.
A supplement to Clinical Endocrinology News. This supplement was sponsored by Dexcom.
• Home Glucose Monitoring
• Continuous Glucose Monitoring
• Summary
Faculty
Steven V. Edelman, MD
Professor of Medicine
University of California, San Diego
La Jolla, California
Dr. Edelman is a consultant to and speaker for Amylin Pharmaceuticals, Inc., Eli Lilly and Company, Novo Nordisk A/S and sanofi-aventis U.S., LLC.
Jacqueline Kung, MD
Endocrinology Fellow
University of California, San Diego Medical Center
VA Medical Center of San Diego
San Diego, California
Dr. Kung has nothing to disclose.
Copyright © 2009 Elsevier Inc.
Preventing Hypoglycemia by Continuous Glucose Monitoring
Preventing Hypoglycemia by Continuous Glucose Monitoring
A1c Management and Modest Weight Loss in Type 2 Diabetes
A supplement to Clinical Endocrinology News and supported by Amylin/Lilly.
Anne Peters, MD, FACP, CDE
Director
University of Southern
California Clinical
Diabetes Programs
Los Angeles, Calif.
Copyright © 2008 Elsevier Inc.
A supplement to Clinical Endocrinology News and supported by Amylin/Lilly.
Anne Peters, MD, FACP, CDE
Director
University of Southern
California Clinical
Diabetes Programs
Los Angeles, Calif.
Copyright © 2008 Elsevier Inc.
A supplement to Clinical Endocrinology News and supported by Amylin/Lilly.
Anne Peters, MD, FACP, CDE
Director
University of Southern
California Clinical
Diabetes Programs
Los Angeles, Calif.
Copyright © 2008 Elsevier Inc.
Medical Avatars—An Innovative Approach to Fostering Health Promotion and Lifestyle Change
Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy
A supplement to Clinical Neurology News. This supplement was supported by Talecris Biotherapeutics. |
|
• Diagnosing CIDP • Therapeutic Options • The ICE Study • Best Practices: Key Takeaways
Faculty/Faculty Disclosures Vera Bril, MD
Copyright © 2008 Elsevier Inc.
|
A supplement to Clinical Neurology News. This supplement was supported by Talecris Biotherapeutics. |
|
• Diagnosing CIDP • Therapeutic Options • The ICE Study • Best Practices: Key Takeaways
Faculty/Faculty Disclosures Vera Bril, MD
Copyright © 2008 Elsevier Inc.
|
A supplement to Clinical Neurology News. This supplement was supported by Talecris Biotherapeutics. |
|
• Diagnosing CIDP • Therapeutic Options • The ICE Study • Best Practices: Key Takeaways
Faculty/Faculty Disclosures Vera Bril, MD
Copyright © 2008 Elsevier Inc.
|
BEST PRACTICES IN: Pediatric Atopic Dermatitis
A supplement to Pediatric News.
This supplement was sponsored by Galderma Laboratories, L.P.
- Introduction
- Genetic Underpinnings of AD
- Filaggrin and Stratum Corneum Dysfunction
- Treatments
- Management Strategies
- Conclusions
To view the supplement, click the image
Faculty/Faculty Disclosure
Lawrence F. Eichenfield, MD
Professor of Pediatrics and Medicine (Dermatology)
University of California, San Diego
Rady Children’s Hospital, San Diego
Dr Eichenfield is an investigator and consultant for Galderma Laboratories, L.P.
Copyright © 2012 Elsevier Inc.
A supplement to Pediatric News.
This supplement was sponsored by Galderma Laboratories, L.P.
- Introduction
- Genetic Underpinnings of AD
- Filaggrin and Stratum Corneum Dysfunction
- Treatments
- Management Strategies
- Conclusions
To view the supplement, click the image
Faculty/Faculty Disclosure
Lawrence F. Eichenfield, MD
Professor of Pediatrics and Medicine (Dermatology)
University of California, San Diego
Rady Children’s Hospital, San Diego
Dr Eichenfield is an investigator and consultant for Galderma Laboratories, L.P.
Copyright © 2012 Elsevier Inc.
A supplement to Pediatric News.
This supplement was sponsored by Galderma Laboratories, L.P.
- Introduction
- Genetic Underpinnings of AD
- Filaggrin and Stratum Corneum Dysfunction
- Treatments
- Management Strategies
- Conclusions
To view the supplement, click the image
Faculty/Faculty Disclosure
Lawrence F. Eichenfield, MD
Professor of Pediatrics and Medicine (Dermatology)
University of California, San Diego
Rady Children’s Hospital, San Diego
Dr Eichenfield is an investigator and consultant for Galderma Laboratories, L.P.
Copyright © 2012 Elsevier Inc.
